Literature DB >> 27140747

Loperamide Abuse Associated With Cardiac Dysrhythmia and Death.

William Eggleston1, Kenneth H Clark2, Jeanna M Marraffa3.   

Abstract

Loperamide is an over-the-counter antidiarrheal with μ-opioid agonist activity. Central nervous system opioid effects are not observed after therapeutic oral dosing because of poor bioavailability and minimal central nervous system penetration. However, central nervous system opioid effects do occur after supratherapeutic oral doses. Recently, oral loperamide abuse as an opioid substitute has been increasing among patients attempting to self-treat their opioid addiction. Ventricular dysrhythmias and prolongation of the QRS duration and QTc interval have been reported after oral loperamide abuse. We describe 2 fatalities in the setting of significantly elevated loperamide concentrations.
Copyright © 2016 American College of Emergency Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27140747     DOI: 10.1016/j.annemergmed.2016.03.047

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  11 in total

1.  Discovery and Characterization of the Biflavones From Ginkgo biloba as Highly Specific and Potent Inhibitors Against Human Carboxylesterase 2.

Authors:  Yun-Qing Song; Rong-Jing He; Dan Pu; Xiao-Qing Guan; Jin-Hui Shi; Yao-Guang Li; Jie Hou; Shou-Ning Jia; Wei-Wei Qin; Sheng-Quan Fang; Guang-Bo Ge
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.810

2.  Loperamide abuse.

Authors:  Tony Antoniou; David N Juurlink
Journal:  CMAJ       Date:  2017-06-12       Impact factor: 8.262

Review 3.  Pharmacologic Treatment of Opioid Use Disorder: a Review of Pharmacotherapy, Adjuncts, and Toxicity.

Authors:  Michael S Toce; Peter R Chai; Michele M Burns; Edward W Boyer
Journal:  J Med Toxicol       Date:  2018-10-30

4.  Loperamide: an emerging drug of abuse and cause of prolonged QTc.

Authors:  George Whittaker; Joseph Newman
Journal:  Clin Med (Lond)       Date:  2021-03       Impact factor: 2.659

5.  Rapalogues as hCES2A Inhibitors: In Vitro and In Silico Investigations.

Authors:  Cheng-Cheng Shi; Yun-Qing Song; Rong-Jing He; Xiao-Qing Guan; Li-Lin Song; Shi-Tong Chen; Meng-Ru Sun; Guang-Bo Ge; Li-Rong Zhang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-01       Impact factor: 2.441

6.  Topical Loperamide-Encapsulated Liposomal Gel Increases the Severity of Inflammation and Accelerates Disease Progression in the Adjuvant-Induced Model of Experimental Rheumatoid Arthritis.

Authors:  Susan Hua; Thilani H Dias; Debbie-Gai Pepperall; Yuan Yang
Journal:  Front Pharmacol       Date:  2017-08-02       Impact factor: 5.810

7.  Functional characteristics of CYP3A4 allelic variants on the metabolism of loperamide in vitro.

Authors:  Qian-Meng Lin; Ying-Hui Li; Qian Liu; Ni-Hong Pang; Ren-Ai Xu; Jian-Ping Cai; Guo-Xin Hu
Journal:  Infect Drug Resist       Date:  2019-09-10       Impact factor: 4.003

Review 8.  Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review.

Authors:  Fabrizio Schifano; Stefania Chiappini; John M Corkery; Amira Guirguis
Journal:  Brain Sci       Date:  2018-04-22

9.  Is there such a thing as a 'lope' dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports.

Authors:  Fabrizio Schifano; Stefania Chiappini
Journal:  PLoS One       Date:  2018-10-04       Impact factor: 3.240

Review 10.  Pharmacological Aspects of Over-the-Counter Opioid Drugs Misuse.

Authors:  Łukasz Sobczak; Krzysztof Goryński
Journal:  Molecules       Date:  2020-08-27       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.